Prolongation of the insulinotropic action of glucagon-like peptide 1 by the dimethyl ester of succinic acid in an animal model of type-2 diabetes

被引:0
|
作者
García-Martínez, JA
Cancelas, J
Villanueva-Peñacarrillo, ML
Valverde, I
Malaisse, WJ
机构
[1] Free Univ Brussels, Expt Med Lab, B-1070 Brussels, Belgium
[2] Fdn Jimenez Diaz, E-28040 Madrid, Spain
关键词
succinic acid dimethyl ester; GLP-1; insulin release; type-2; diabetes;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Adult rats, that had been injected with streptozotocin during the neonatal period, received a primed constant infusion of succinic acid dimethyl ester (SAD; 0.5 mu mol followed by 0.25 mu mol . min(-1), both per g body wt.) in saline for 15 min and, at the 5th min of such an infusion, an intravenous injection of GLP-1 (5 pmol per g body wt.). Within 2 min, the ester increased the plasma insulin concentration by 0.33+/-0.05 nM. Likewise, within 2 min, GLP-1 provoked a marked increase in plasma insulin concentration; such an increase was comparable in rats infused with either saline or SAD, with an overall mean value of 0.93+/-0.07 nM. In the rats infused with SAD, however, the secretory response to GLP-1 appeared more sustained than in the saline-infused animals. For instance, the paired ratio for the insulinogenic index at 10/2 min after GLP-1 injection averaged 30.5+/-4.0% in SAD-infused rats, as compared (P<0.025) to only 17.0+/-2.5% in saline-infused animals. These findings suggest that succinic acid esters could be used to prolong the insulinotropic action of GLP-1 in the treatment of type-2 diabetes.
引用
收藏
页码:319 / 321
页数:3
相关论文
共 50 条
  • [41] Is secretion of glucagon-like peptide-1 reduced in type 2 diabetes mellitus?
    Meier, Juris J.
    Nauck, Michael A.
    NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2008, 4 (11): : 606 - 607
  • [42] Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond
    Viljoen, Adie
    Bain, Stephen C.
    ENDOCRINOLOGY AND METABOLISM, 2023, 38 (01) : 25 - 33
  • [43] Additive effects of glucagon-like peptide 1 and pioglitazonein patients with type 2 diabetes
    Zander, M
    Christiansen, A
    Madsbad, S
    Holst, JJ
    DIABETES CARE, 2004, 27 (08) : 1910 - 1914
  • [44] Constitutive expression of glucagon-like peptide 1 for gene therapy of type 2 diabetes
    Parsons, GB
    Yu, D
    Souza, DW
    Wu, H
    Wadsworth, S
    Gregory, R
    Armentano, D
    DIABETES, 2005, 54 : A146 - A146
  • [45] Glucagon-like peptide 1 agonists for type 2 diabetes, weight loss, or both?
    Keedy, Chelsea A.
    Bland, Christopher M.
    JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2024, 37 (05): : 12 - 14
  • [46] Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists
    Hansen, K. B.
    Knop, F. K.
    Holst, J. J.
    Vilsboll, T.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (08) : 1154 - 1160
  • [47] The role of glucagon-like peptide 1 for the postprandial effects of metformin in type 2 diabetes
    Hansen, L. S.
    Gasbjerg, L. S.
    Bronden, A.
    Dalsgaard, N. B.
    Bahne, E.
    Stensen, S.
    Hellmann, P. H.
    Rehfeld, J.
    Holst, J. J.
    Vilsboll, T.
    Knop, F. K.
    DIABETOLOGIA, 2019, 62 : S57 - S58
  • [48] Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus
    Guyton, Justinne
    Jeon, Michelle
    Brooks, Amie
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2019, 76 (21) : 1739 - 1748
  • [49] Glucagon-like peptide 1 improved glycemic control in type 1 diabetes
    Margaret T Behme
    John Dupré
    Thomas J McDonald
    BMC Endocrine Disorders, 3 (1)
  • [50] Absence of a memory effect for the insulinotropic action of glucagon-like peptide 1 (GLP-1) in healthy volunteers
    Meier, S
    Hücking, K
    Ritzel, R
    Holst, JJ
    Schmiegel, WH
    Nauck, MA
    HORMONE AND METABOLIC RESEARCH, 2003, 35 (09) : 551 - 556